

## *Curriculum Vitae*

**Michael Thomas**      Professor Dr. med.

### **University Education**

1997              Habilitation Internal Medicine, Heinrich-Heine University Düsseldorf  
1987              Doctorate Medicine, Justus-Liebig University Giessen  
1979-1985        Medical School, University of Gießen

### **Scientific Career**

Since 2016      Board of Directors, Working Group on Medical Oncology, German Cancer Society  
Since 2015      Board of Directors, National Center on Tumor Diseases (NCT), Heidelberg  
2011-2023      Co-Coordinator, Disease Area Lung Cancer, German Center on Lung Research (DZL);  
                         Excellence Initiative of the German Ministry of Education and Research (BMBF)  
Since 2005      Head, Dpt. Thoracic Oncology, Thoraxklinik Heidelberg  
Since 2005      Professor (W3), Med. Oncology of Thoracic Malignancies, University Heidelberg  
2010-2016      Coordinator, Working Group on Thoracic Oncology, German Cancer Society  
2007-2009      Board of Directors, German Respiratory Society  
2006-2013      Co-Chair, ABC (Aktion Bronchialkarzinom) – Clinical Trials Group on Lung Cancer  
2004-2005      Professor (C3), Pulmonology - Internal Medicine, University Münster  
1997-2005      Consultant / Associate Professor, Internal Medicine, University Münster  
1995-2003      Head Coordinator, German Lung Cancer Cooperative Group (GLCCG)  
1994-1996      Fellowship, Pulmonology, University Hospital Münster  
1992-1995      Coordinator, German Lung Cancer Cooperative Group (GLCCG)  
1992-1994      Fellowship, Hematology / Oncology, University Hospital Münster  
1987-1992      Residency, Internal Medicine, University Hospital Düsseldorf  
1986-1987      Internship, Internal Medicine, Ev. Krankenhaus Gießen

### **Awards and Honors**

2010              John-Mendelsohn - Clinical Trial Award - German Cancer Society  
2002              AIO–German Cancer Society Award for outstanding achievements in the clinical  
                         research of cancer treatment

### **Citation Record**

*Total citations: 23.129; h-index: 61 (Scopus August 5<sup>th</sup>, 2024)*

## Top-10 selected Publications

Rieckmann LM, Spohn M, Ruff L, Agorku D, Becker L, Borchers A, Krause J, O'Reilly R, Hille J, Velthaus-Rusik JL, Beumer N, Günther A, Willnow L, Imbusch CD, Iglauer P, Simon R, Franzenburg S, Winter H, **Thomas M**, Bokemeyer C, Gagliani N, Krebs CF, Sprick M, Hardt O, Riethdorf S, Trumpp A, Stoecklein NH, Peine S, Rosenstiel P, Pantel K, Loges S, Janning M. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells. **Mol Cancer** 2024; 23(1):93. doi: [10.1186/s12943-024-01984-2](https://doi.org/10.1186/s12943-024-01984-2).

Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Stenzinger A, **Thomas M**. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC. *J Thorac Oncol* 2023; 18(6):744-754. doi: [10.1016/j.jtho.2023.01.086](https://doi.org/10.1016/j.jtho.2023.01.086).

Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wessler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, **Thomas M**. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. *Eur J Cancer*. 2022; 170:106-118. doi: [10.1016/j.ejca.2022.04.020](https://doi.org/10.1016/j.ejca.2022.04.020).

Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar AL, Bruckner LM, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth FJF, Heussel CP, El Shafie RA, Schneider MA, Muley T, Meister M, Faehling M, Fischer JR, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, **Thomas M**. Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing. **Lung Cancer** 2020; 148:105-12. doi: [10.1016/j.lungcan.2020.08.007](https://doi.org/10.1016/j.lungcan.2020.08.007).

Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, **Thomas M**. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer. **Int J Cancer** 2018; 142(12):2589-98. doi: [10.1002/ijc.31275](https://doi.org/10.1002/ijc.31275).

**Thomas M**, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Dómine Gómez M, Kollmeier J, Sadjadian P, Fröhling KP, Huber R, Wolf M, IMPULSE study team. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study. **Ann Oncol** 2018; 29(10):2076-2084. doi: [10.1093/annonc/mdy326](https://doi.org/10.1093/annonc/mdy326).

Christopoulos P, Engel-Riedel W, Grohe C, Kropf-Sanchen C, von Pawel J, Gütz S, Kollmeier J, Eberhardt W, Ukena D, Baum V, Nimmrich I, Sieder C, Schnabel P, M. Serke M, **Thomas M**. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. **Ann Oncol** 2017; 28(2):1898-1902. doi: [10.1093/annonc/mdx268](https://doi.org/10.1093/annonc/mdx268).

**Thomas M**, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, von Eiff M, Witt C, Kollmeier J, Müller E, Schenk M, Schröder M, Villalobos M, Reinmuth N, Penzel R, Schnabel P, Acker T, Reuss A, Wolf M. Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous non-small cell lung cancer. **Eur Respir J** 2015; 46(1):219-229. doi: [10.1183/09031936.00229014](https://doi.org/10.1183/09031936.00229014).

Reinmuth N, Stumpf A, Stumpf P, Muley T, Kobinger S, Hoffmann H, Herth FJ, Schnabel PA, Warth A, Bischoff H, **Thomas M**. Characteristics and outcome of patients with second primary lung cancer. **Eur Respir J** 2013; 42(6):1668-1676. doi: [10.1183/09031936.00022512](https://doi.org/10.1183/09031936.00022512).

Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatidis G, Zuna I, Griesinger F, **Thomas M**. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. **Ann Oncol** 2013; 24(4):986-992. doi: [10.1093/annonc/mds578](https://doi.org/10.1093/annonc/mds578).